» Articles » PMID: 32748864

Effects of Chitosan Oligosaccharide on Plasma and Hepatic Lipid Metabolism and Liver Histomorphology in Normal Sprague-Dawley Rats

Overview
Journal Mar Drugs
Publisher MDPI
Specialties Biology
Pharmacology
Date 2020 Aug 5
PMID 32748864
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Chitosan oligosaccharide is known to ameliorate hypercholesterolemia and diabetes. However, some studies found that chitosan oligosaccharide might induce mild to moderate hepatic damage in high-fat (HF) diet-induced obese rats or diabetic rats. Chitosan oligosaccharide can be as a dietary supplement, functional food, or drug. Its possible toxic effects to normal subjects need to be clarified. This study is designed to investigate the effects of chitosan oligosaccharide on plasma and hepatic lipid metabolism and liver histomorphology in normal Sprague-Dawley rats. Diets supplemented with 5% chitosan oligosaccharide have been found to induce liver damage in HF diet-fed rats. We therefore selected 5% chitosan oligosaccharide as an experimental object. Rats were divided into: a normal control diet group and a normal control diet +5% chitosan oligosaccharide group. The experimental period was 12 weeks. The results showed that supplementation of 5% chitosan oligosaccharide did not significantly change the body weight, food intake, liver/adipose tissue weights, plasma lipids, hepatic lipids, plasma levels of AST, ALT, and TNF-α/IL-6, hepatic lipid peroxidation and anti-oxidative enzyme activities, fecal lipids, and liver histomorphology in normal rats. These findings suggest that supplementation of 5% chitosan oligosaccharide for 12 weeks may not induce lipid metabolism disorder and liver toxicity in normal rats.

Citing Articles

Modulation of the Cardiovascular Risk in Type 1 Diabetic Rats by Endurance Training in Combination with the Prebiotic Xylooligosaccharide.

Choneva M, Delchev S, Hrischev P, Dimov I, Boyanov K, Dimitrov I Int J Mol Sci. 2024; 25(18).

PMID: 39337515 PMC: 11432573. DOI: 10.3390/ijms251810027.


THE THERAPEUTIC EFFECT OF ALLOPURINOL IN FATTY LIVER DISEASE IN RATS.

Barisik V, Korkmaz H, Cekdemir Y, Torlak D, Aktug H, Yavasoglu A Acta Endocrinol (Buchar). 2023; 19(2):155-162.

PMID: 37908883 PMC: 10614584. DOI: 10.4183/aeb.2023.155.


Anti-Obesity Effects of Chitosan and Its Derivatives.

Shagdarova B, Konovalova M, Varlamov V, Svirshchevskaya E Polymers (Basel). 2023; 15(19).

PMID: 37836016 PMC: 10575173. DOI: 10.3390/polym15193967.


Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.

Yu T, Cai Z, Chang X, Xing C, White S, Guo X Orthop Surg. 2023; 15(9):2244-2259.

PMID: 37403654 PMC: 10475694. DOI: 10.1111/os.13806.


Antidiabetic Properties of Chitosan and Its Derivatives.

Tzeng H, Liu S, Chiang M Mar Drugs. 2022; 20(12).

PMID: 36547931 PMC: 9782916. DOI: 10.3390/md20120784.


References
1.
Kim J, Chang I, Kim H, Yoon S . Long-term effects of chitosan oligosaccharide in streptozotocin-induced diabetic rats. Islets. 2010; 1(2):111-6. DOI: 10.4161/isl.1.2.9143. View

2.
Ju C, Yue W, Yang Z, Zhang Q, Yang X, Liu Z . Antidiabetic effect and mechanism of chitooligosaccharides. Biol Pharm Bull. 2010; 33(9):1511-6. DOI: 10.1248/bpb.33.1511. View

3.
Liu S, Chiu C, Huang L, Chiang M . Resistant Maltodextrin Ameliorates Altered Hepatic Lipid Homeostasis via Activation of AMP-Activated Protein Kinase in a High-Fat Diet-Fed Rat Model. Nutrients. 2019; 11(2). PMC: 6413141. DOI: 10.3390/nu11020291. View

4.
Naveed M, Phil L, Sohail M, Hasnat M, Ashraf Baig M, Ihsan A . Chitosan oligosaccharide (COS): An overview. Int J Biol Macromol. 2019; 129:827-843. DOI: 10.1016/j.ijbiomac.2019.01.192. View

5.
Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View